Abstract
Summary The effects of phenformin, metformin, and Atromid on blood fibrinolytic activity, plasma fibrinogen, and serum cholesterol levels were compared in a study of 36 out-patients with occlusive vascular disease. Atromid was the least satisfactory fibrinolytic drug, having only a transient effect on the blood clot lysis time, though a more sustained effect on the euglobulin lysis time. A larger dose of metformin reduced the blood fibrinolytic time and euglobulin lysis time concordantly, but a smaller dose was less effective. Phenformin had an effect comparable to metformin, but partial loss of increased fibrinolytic activity occurred after 3–4 months' treatment with this drug. Serum cholesterol was reduced by Atromid, showed a transient reduction with metformin, and a sustained reduction with phenformin. Plasma fibrinogen was reduced by phenformin. Metformin and Atromid had no appreciable effect on the level of this protein.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
